Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep576 | Diabetes therapy | ECE2016

Trends and differences between sexes in control of diabetes and cardiovascular risk factors from 2004 to 2014

Vicente Almudena , Cortes Claudia , Olivar Monica , Martinez Ana , Sastre Julia , Marco Amparo , Luque Ines , Lopez Jose

Background: Poorer control of risk factors for cardiovascular disease (cvd) has been reported in diabetic women compared with men.Objective: To investigate whether control of diabetes and risk factors for cvd differ between sexes in a cohort of diabetic patients monitored at an outpatient endocrinology clinic from 2004 till 2014.Design: Observational, retrospective cohort study.Patients and methods: A cohort ...

ea0037ep272 | Calcium and Vitamin D metabolism | ECE2015

Cinacalcet remains effective in primary hyperparathyroidism after 4 years of treatment

Luque-Fernandez Ines , Vall Florentino Del , Luque Alessandra , Vicente Almudena , Sastre Julia , Marco Amparo

Introduction: Cinacalcet is an oral calcimimetic indicated in treatment of primary hyperparathyroidism in patients who are unable to undergo parathyroidectomy: do not accept surgery, there is failure of previous surgery or serious comorbidity that makes surgery impossible.Methods: Descriptive study that includes nine patients with primary hyperparathyroidism who have completed at least 48 months of treatment with cinacalcet (seven patients refusal to par...

ea0032p482 | Diabetes | ECE2013

Are there gender differences in liraglutide response in adults with type 2 diabetes?

Sastre Julia , Vicente Almudena , Maqueda Esther , Luque Ines , Castro Enrique , Marco Amparo , Pena Virginia , Lopez Jose

Background: Recent reports suggest that female sex could be an indicator of better response to liraglutide in patients included in clinical trials.Aim: To compare efficacy of liraglutide in women and men with type 2 diabetes mellitus (T2DM), in real clinical practice.Patients and methods: Our study included 116 patients with T2DM and obesity (BMI >30) attending outpatient clinic, which initiated with liraglutide (0.6 mg/daily f...

ea0032p941 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Clinical presentation, treatment approach and outcomes of patients with prolactinomas in real-life clinical practice: a single center experience

Vicente Almudena , Satre Julia , Zaballos Florentino , Luque Ines , Luque Alessandra , Castro Enrique , Maqueda Esther , Marco Amparo , Lopez Jose

Introduction: Generously supported by IPSEN)-->Prolactin (PRL) -secreting adenomas are about 40% of all pituitary adenomas. Their clinical symptoms are mainly related to development of secondary hypogonadism and/or tumor mass effects. Dopamine agonists (DA) are first-line drugs for prolactinoma patients due to their effectiveness in normalizing PRL levels and shrinking tumour mass. Surgery is an option for DA failure or tumour mass e...

ea0016p781 | Thyroid | ECE2008

Iodine status in pregnant women: do they have sufficient information about the importance of iodine nutrition during the pregnancy?

Marco Amparo , Vicente Almudena , Castro Enrique , Canovas Barbara , Sastre Julia , Cruces Eva , Maqueda Esther , Iglesias Maria Lopez , Lopez Jose Lopez

The recommended nutrient intake (RNI) for iodine during pregnancy has been re-evaluated in 2005 by an international expert committee under the auspices of the World Health Organization (WHO). The consensus reached was that the RNI for iodine during pregnancy should range between 200 and 300 μ/d with an average of 250 μ/d.To asses the adequacy of the iodine intake during pregnancy in a population, urinary iodine concentration (UIC) should be mea...